CoChat

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

Open access
Cirenajwis, Helena, Ekedahl, Henrik, Lauss, Martin, Harbst, Katja, Carneiro, Ana, Enoksson, Jens, Rosengren, Frida, Werner-Hartman, Linda, Törngren, Therese, Kvist, Anders, Fredlund, Erik, Bendahl, Pär-Ola, Jirström, Karin, Lundgren, Lotta, Howlin, Jillian, Borg, Åke, Gruvberger-Saal, Sofia K., Saal, Lao H., Nielsen, Kari, Ringnér, Markus, Tsao, Hensin, Olsson, Håkan, Ingvar, Christian, Staaf, Johan, Jönsson, Göran · 2015 · Oncotarget
Cited by 192

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Helena Cirenajwis 1 , Henrik Ekedahl 2 , Martin Lauss 1 , Katja Harbst 1 , Ana Carneiro 1,3 , Jens Enoksson 4 , Frida Rosengren 1 , Linda Werner-Hartman 1 , Therese Törngren 1 , Anders Kvist 1 , Erik Fredlund 5 , Pär-Ola Bendahl 1 , Karin Jirström 4 , Lotta Lundgren 1,3 , Jillian Howlin 1 , Åke Borg 1 , Sofia K. Gruvberger-Saal 1 , Lao H. Saal 1 , Kari Nielsen 6 , Markus Ringnér 1 , Hensin Tsao 7,8 , Håkan Olsson 1,3 , Christian Ingvar 2 , Johan Staaf 1 , Göran Jönsson 1 1 Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden 2 Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden 3 Department of Oncology, Skåne University Hospital, Lund University, Lund, Sweden 4 Department of Clinical Pathology, Skåne University Hospital, Lund University, Lund, Sweden 5 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden 6 Department of Dermatology, Helsingborg General Hospital, Helsingborg, Sweden 7 Department of Dermatology, Harvard Medical School, Boston, USA 8 Wellman Center for Photomedicine, MGH Cancer Center, Massachusetts General Hospital, Boston, USA Correspondence to: Göran Jönsson, email: // Keywords : gene expression, melanoma, BRAF, BRAF inhibitor, mutation Received : January 09, 2015 Accepted : February 27, 2015 Published : March 26, 2015 Abstract Melanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and normal-like), which are predictive of survival outcome as well as informative of biology. Herein, we employed a population-based metastatic melanoma cohort and external cohorts to determine the prognostic and predictive significance of the gene expression phenotypes. We performed expression profiling on 214 cutaneous melanoma tumors and found an increased risk of developing distant metastases in the pigmentation (HR, 1.9; 95% CI, 1.05-3.28; P =0.03) and proliferative (HR, 2.8; 95% CI, 1.43-5.57; P =0.003) groups as compared to the high-immune response group. Further genetic characterization of melanomas using targeted deep-sequencing revealed similar mutational patterns across these phenotypes. We also used publicly available expression profiling data from melanoma patients treated with targeted or vaccine therapy in order to determine if our signatures predicted therapeutic response. In patients receiving targeted therapy, melanomas resistant to targeted therapy were enriched in the MITF-low proliferative subtype as compared to pre-treatment biopsies ( P =0.02). In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3655

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Cirenajwis, H., Ekedahl, H., Lauss, M., Harbst, K., Carneiro, A., Enoksson, J., Rosengren, F., Werner-Hartman, L., Törngren, T., Kvist, A., Fredlund, E., Bendahl, P.-O., Jirström, K., Lundgren, L., Howlin, J., Borg, Å., Gruvberger-Saal, S. K., Saal, L. H., Nielsen, K., Ringnér, M., Tsao, H., Olsson, H., Ingvar, C., Staaf, J., & Jönsson, G.
Venue
Oncotarget
Published
2015-03-26
Volume
6
Issue
14
Pages
12297-12309
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1854900052
Cited by
192
References
12
FWCI
6.05
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.